English >>
TOPページ
学術雑誌
学会発表
(最終更新日:2022-06-03 11:12:43)
タニオカ ヒロアキ
谷岡 洋亮
所属
川崎医科大学 医学部 臨床医学 臨床腫瘍学
職種
特任講師
■
学術雑誌
1.
2022/05
原著
Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study
2.
2022/05
原著
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
3.
2021/11
原著
Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer
4.
2021/05/12
原著
Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
5.
2021/05
原著
Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations
6.
2021/03/17
原著
Safety and e cacy of panitumumab in combination with tri uridine/ tipiracil for pre‐treated patients with unresectable, metastatic colorectal cancer with wild‐type RAS: The phase 1/2 APOLLON study
7.
2021/02
原著
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI)
8.
2020/11/21
原著
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial
9.
2020/08/31
原著
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
10.
2020/08/24
原著
Adoptive immunotherapy for gastric cancer using zoledronate‑activated killer cells: A prospective observational study
11.
2020/07/21
総説
Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary
12.
2020/05/15
その他
胆道癌・膵癌に対する免疫療法
13.
2020/05/01
症例報告
胃癌骨転移に対するデノスマブ投与後に著明な低カルシウム血症が遷延した一例
14.
2020/04/18
原著
Prognostic nutritional index as a predictor of postoperative outcome in patients aged 85 years or older after colorectal cancer surgery
15.
2020/03/24
原著
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
16.
2020/02/03
原著
Upregulation of microRNA‐31 is associated with poor prognosis in patients with advanced colorectal cancer
17.
2020/01/21
原著
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
18.
2019/12
症例報告
胃癌治癒切除後の傍大動脈リンパ節再発に対してサルベージ手術を含む集学的治療を行い長期生存を得た1例
19.
2019/12
原著
皮下埋め込み型中心静脈ポート留置消化器癌患者におけるカテーテル関連静脈血栓発現頻度の検討
20.
2019/10/11
原著
The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
21.
2019/05
原著
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
22.
2019/02
原著
Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the e cacy and safety
23.
2018/10
原著
Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer
24.
2018/10
その他
【食道癌(第2版)-基礎・臨床研究の進歩-】食道癌の生物学 食道癌患者における免疫逃避機構
25.
2018/09
原著
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial
26.
2018/08
原著
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer
27.
2018/07
原著
Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical bene t in response to prior cetuximab: A retrospective study
28.
2018/07
その他
特集 免疫チェックポイント阻害剤の副作用と対策 緒言
29.
2018/03
原著
Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
5件表示
全件表示(29件)
■
学会発表
1.
2022/03/04
REVIVE試験:ニボルマブの奏効別の救済化学療法の治療効果について (口頭発表,一般)
2.
2022/02/17
A Phase III trial of sequential versus combination in metastatic colorectal cancer: C-Cubed study (口頭発表,一般)
3.
2022/02/17
Fluctuating PD-1 ratio in blood may predict clinical outcome of upper gastrointestinal cancer patients under ICI therapy (ポスター,一般)
4.
2022/02/17
RAS/RAF/Microsatellite statusに間葉型を加えた新しいサブタイプによる大腸癌のPrecision Medicine (ポスター,一般)
5.
2022/02/17
REVIVE study: An Observational Study in Chemotherapy (CTx) after Nivolumab (NIVO) for Advanced Gastric Cancer (AGC) (口頭発表,一般)
6.
2022/01/21
A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer: The C-cubed study (ポスター,一般)
7.
2022/01/21
REVIVE study: A prospective observational study in chemotherapy (CTx) after nivolumab (NIVO) therapy for advanced gastric cancer (AGC) (ポスター,一般)
8.
2021/11/12
MLH1 Methylation およびBRAF V600E 変異同定DNA chip によるリンチ症候群除外診断技術の確立と実用化にむけて (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
9.
2021/10/22
胃癌ニボルマブ投与による末梢血 PD1CD8 陽性 T リンパ球変化は効果予測となりうる (ポスター,一般)
10.
2021/09/12
口唇にできたSCCの切除後,食道癌が発見された1例 (口頭発表,一般)
11.
2021/05/21
胃癌薬物療法における投与前低好中球リンパ球比は良好な予後予測因子となりうる(主題5) (口頭発表,一般)
12.
2021/03/11
切除不能胃癌に対するZAK細胞移入療法の臨床成績 (ポスター,一般)
13.
2020/11/19
Cell-free and concentrated ascites reinfusion therapy (CART)におけるNeutrophil to Lymphocyte Ratioと予後の関係 (シンポジウム・ワークショップ・パネルディスカッション等)
14.
2020/11/19
抗VEGF抗体RAMUCIRUMABによる肝転移巣の肝類洞血小板凝集 (特別・招待講演等)
15.
2020/11/19
切除不能胃癌患者の各治療開始前好中球リンパ球比と抗腫瘍効果の検討:3次治療ニボルマブの抗腫瘍効果を中心に (シンポジウム・ワークショップ・パネルディスカッション等)
16.
2020/10/23
大腸癌肝転移における抗VEGF抗体による肝類洞血小板凝集効果と肝切除 (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
17.
2020/10/22
進行性消化管間質腫瘍に対するレゴラフェニブ療法により誘発された多形紅斑の2例 (ポスター,一般)
18.
2020/10/22
低好中球リンパ球比は胃癌化学療法の良好な抗腫瘍効果の予測因子となりうる (口頭発表,一般)
19.
2020/10/22
腹膜濾過濃縮再静注法を受けた難治性腹膜播種患者の好中球リンパ球比の予後徴候の検討 (ポスター,一般)
20.
2020/01/23
A phase II study of FOLFOXIRI plus bevacizumab (Bmab) as initial chemotherapy for patients (pts) with untreated metastatic colorectal cancer (mCRC): TRICC1414 (Be TRI). (ポスター,一般)
21.
2020/01/23
Multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII). (ポスター,一般)
22.
2019/10/26
Precision Palliative Active Care Programは高流量酸素投与癌患者の旅行を可能にする (ポスター,一般)
23.
2019/10/26
化学療法未治療の進行・再発大腸癌に対するFOLFOXIRI+ベバシズマブ療法の安全性 (口頭発表,一般)
24.
2019/10/24
Genetic Stable胃癌における病理分子生物学的特徴の検討 (口頭発表,一般)
25.
2019/10/24
Precision Palliative Active Care Programを用いた急性期型緩和ケア病棟への試み (ポスター,一般)
26.
2019/09/29
Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII) (ポスター,一般)
27.
2019/09/29
Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study (ポスター,一般)
28.
2019/07/18
Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer (口頭発表,一般)
29.
2019/07/18
Update on phase II trial of cetuximab plus S-1/oxaliplatin (SOX) for metastatic colorectal cancer (mCRC): JACCRO CC-06 (口頭発表,一般)
30.
2019/07/18
デノスマブ投与後に重度の低カルシウム血症が遷延した一例 (ポスター,一般)
31.
2019/07/18
切除不能進行・再発胃癌患者の二次化学療法中における末梢神経障害と薬剤効果を検討する前向き多施設共同観察研究 (ポスター,一般)
32.
2019/07/05
Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors (ポスター,一般)
33.
2019/07/04
Relationship between peripheral neuropathy and effectiveness in second-line chemotherapy for unresectable advanced gastric cancer: a prospective, observational, multicenter study protocol (ポスター,一般)
34.
2019/06/21
CVポート留置消化器癌患者におけるカーテル関連静脈血栓発現頻度の検討 (口頭発表,一般)
35.
2019/06/21
胃癌治癒切除後の傍大動脈リンパ節単発再発に対して集学的治療を行い長期生存を得た1例 (口頭発表,一般)
36.
2019/06/14
KRAS 変異 Hypermutant 大腸癌の特長:A Retrospective Analysis of 1,052 Japanese Colorectal Cancer Patients without Treatment of Immuno-checkpoint Inhibitors. (ポスター,一般)
37.
2019/06/14
Pembrolizumabによるギラン・バレー症候群が示唆されたMSI-High大腸癌の一例 (ポスター,一般)
38.
2019/06/03
Validation of biomarkers of preoperative chemoradiotherapy for advanced low rectal cancer and extraction of the high-risk group of recurrence (ポスター,一般)
39.
2019/05/16
切除不能進行大腸癌に対する2次治療としてのXELIRI + bevacizumab第II相試験 −RAS・BRAF変異並びにUGT1A遺伝子多型と効果・毒性との関連− (ポスター,一般)
40.
2019/04/19
リンチ症候群関連胃神経内分泌癌の一例 (口頭発表)
41.
2019/04/18
進行下部直腸癌に対する術前放射線化学療法におけるバイオマーカーによるグルーピング (口頭発表)
42.
2019/04/01
Comparing effects of small molecular weight compounds on proliferation and chemotaxis of pancreatic cancer cells (ポスター,一般)
43.
2019/04
紡錘細胞型・硬化型横紋筋肉腫の一例
44.
2019/01/19
Analysis of UGT1A's polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer. (ポスター,一般)
45.
2019/01/19
CEA response at four weeks as an early predictor for outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab-based chemotherapy: A STEP-analysis in the JACCRO CC-05/06 trials. (ポスター,一般)
46.
2019/01/19
Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study. (ポスター,一般)
47.
2018/11/24
Efficacy of Ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer. (ポスター,一般)
48.
2018/11/24
Incidence of catheter-related thrombosis in patients with long-term indwelling central venous catheter who received chemotherapies for unresectable advanced digestive cancers (ポスター,一般)
49.
2018/11/10
遺伝性大腸癌の診断と治療 Lynch症候群を含むHypermutant大腸癌における臨床病理学的特徴 (口頭発表,シンポジウム・ワークショップ・パネルディスカッション等)
50.
2018/10/22
Heat shock protein 90 (HSP90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors (ポスター,一般)
51.
2018/10/21
Distinct Clinico-pathological Features of Hypermutant Colorectal Cancers with POLE Pathogenic Mutations, Lynch Syndrome and Sporadic MSI Analyzed over 1,000 Colorectal Cancer Patients (ポスター,一般)
52.
2018/10/20
化学療法未治療の進行・再発大腸癌に対するFOLFOXIRI+ベバシズマブ療法の初期安全性 (口頭発表,一般)
53.
2018/10/13
神経線維症1型に合併したGISTの3例 (口頭発表,一般)
54.
2018/07/19
Lynch 症候群に関連した胃神経内分泌癌の一例 (ポスター,一般)
55.
2018/07/19
RAS野生型進行再発大腸癌に対するパニツムマブとTAS-102併用療法を検討する第 I/II 試験:APOLLON試験 (口頭発表,一般)
56.
2018/07/19
小児・AYA世代発症消化管間質腫瘍の治療例の検討 (ポスター,一般)
57.
2018/07/19
消化器癌におけるCVポート留置による深部静脈血栓症発現頻度の検討 (ポスター,一般)
58.
2018/07/13
循環血液中Ago2複合体microRNA測定による大腸癌スクリーニングと化学療法効果予測 (口頭発表,一般)
59.
2018/06/20
A phase I/II study of panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: APOLLON study (ポスター,一般)
60.
2018/06/09
Nivolumab投与後にリウマチ性多発筋痛症を発症した胃癌の1例 (口頭発表,一般)
61.
2018/06/08
Germline mutationを伴う多発性消化管間質腫瘍の1例 (ポスター,一般)
62.
2018/06/04
Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402. (ポスター,一般)
63.
2018/06/03
A randomized phase II study of weekly paclitaxel +/- trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT). (ポスター,一般)
64.
2018/06/03
APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC). (ポスター,一般)
65.
2018/06/03
Biomarker study for trastuzumab continuation beyond progression in a randomized phase II trial of weekly paclitaxel+/-trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum (WJOG7112G). (ポスター,一般)
66.
2018/03/08
A phase II study of S-1 and oxaliplatin for HER2-negative advanced gastric cancer (KSCC1501A) (ポスター,一般)
5件表示
全件表示(66件)